Really the whole concept is flawed wrt to pneumonia and the idea that Resapp might be able to differentiate viral pneumonia from bacterial pneumonia in order to guide treatment.
https://www.news-medical.net/news/2...-sufficiently-pathognomonic-in-pneumonia.aspx
Fortunately with lobar pneumonia the pathonomonic signs of consolidation with will be apparent on ausculation with a stethoscope and visible on a plain chest X-ray. However I do not believe there is any characteristic cough that could be associated with lobar pneumonia. It can't work reliably for this illness.
- Forums
- ASX - By Stock
- RAP
- What sp will be if 2nd refined study is positive
What sp will be if 2nd refined study is positive, page-91
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAP (ASX) to my watchlist
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online